

# Michael S Ewer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8668957/publications.pdf>

Version: 2024-02-01

32  
papers

2,059  
citations

623734

14  
h-index

477307

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

2393  
citing authors

#	ARTICLE	IF	CITATIONS
1	BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. <i>Cancers</i> , 2022, 14, 2596.	3.7	8
2	Cardiac Safety of Osimertinib: A Review of Data. <i>Journal of Clinical Oncology</i> , 2021, 39, 328-337.	1.6	44
3	Reply to K. Anand et al and K. Kunimasa. <i>Journal of Clinical Oncology</i> , 2021, 39, 2051-2052.	1.6	0
4	TAVR and cancer: machine learning-augmented propensity score mortality and cost analysis in over 30 million patients. <i>Cardio-Oncology</i> , 2021, 7, 25.	1.7	7
5	Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100233.	1.1	1
6	An overview of a different type of cardio-oncology gathering: summary of the COMP (cardio-oncology multidisciplinary practice) meeting held in Houston Texas, January 2020. <i>Cardio-Oncology</i> , 2020, 6, 20.	1.7	1
7	Cancer patients in cardiology: how to communicate with patients with special psychological needs and manage their cardiac problems in daily clinical practice. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 286-291.	1.5	4
8	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 135-141.	0.4	37
9	False Positive Cardiotoxicity Events in Cancer-Related Clinical Trials: Risks Related to Imperfect Noninvasive Parameters. <i>Chemotherapy</i> , 2018, 63, 324-329.	1.6	14
10	Stress-Induced Cardiomyopathy in Cancer Patients. <i>American Journal of Cardiology</i> , 2017, 120, 2284-2288.	1.6	50
11	Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?. <i>Oncologist</i> , 2016, 21, 399-401.	3.7	2
12	Trastuzumab cardiotoxicity: the age-old balance of risk and benefit. <i>British Journal of Cancer</i> , 2016, 115, 1441-1442.	6.4	2
13	Cardiac safety of afatinib: a review of data from clinical trials. <i>Cardio-Oncology</i> , 2015, 1, 3.	1.7	15
14	Cardio-oncology: an ongoing evolution. <i>Future Oncology</i> , 2015, 11, 2059-2066.	2.4	12
15	The anthracycline-trastuzumab interaction: a lesson in not jumping to confusion. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 321-322.	8.7	5
16	Cardiotoxicity of anticancer treatments. <i>Nature Reviews Cardiology</i> , 2015, 12, 547-558.	13.7	284
17	Mechanisms underlying trastuzumab activity are complex. <i>Nature Reviews Cardiology</i> , 2015, 12, 669-669.	13.7	1
18	Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 152-158.	0.4	34

#	ARTICLE	IF	CITATIONS
19	Screening for Cardiac Risk Before Anthracycline Administration: What Are The Real Benefits?. <i>Clinical Breast Cancer</i> , 2012, 12, 1-3.	2.4	1
20	A Historical Perspective of Anthracycline Cardiotoxicity. <i>Heart Failure Clinics</i> , 2011, 7, 363-372.	2.1	45
21	Cardiac dysfunction after cancer treatment. <i>Texas Heart Institute Journal</i> , 2011, 38, 248-52.	0.3	11
22	A woman's heart. <i>Cancer</i> , 2009, 115, 1813-1826.	4.1	81
23	Sunitinib-related cardiotoxicity: an interdisciplinary issue. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 364-365.	3.3	5
24	Is trastuzumab associated with adverse cardiac effects in patients with breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 192-193.	4.3	4
25	Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. <i>Clinical Breast Cancer</i> , 2007, 7, 600-7.	2.4	27
26	Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment. <i>Journal of Clinical Oncology</i> , 2005, 23, 7820-7826.	1.6	640
27	Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity. <i>Journal of Clinical Oncology</i> , 2005, 23, 2900-2902.	1.6	545
28	Characteristics of cardiac arrest in cancer patients as a predictor of survival after cardiopulmonary resuscitation. , 2001, 92, 1905.		3
29	Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 471-478.	2.3	51
30	Late doxorubicin-associated cardiotoxicity in children. <i>Cancer</i> , 1994, 74, 182-188.	4.1	74
31	Cardiac Diastolic Function in Pediatric Patients Receiving Doxorubicin. <i>Acta OncolÃ³gica</i> , 1994, 33, 645-649.	1.8	33
32	Postoperative atrial fibrillation in cancer surgery: Preoperative risks and clinical outcome. <i>Journal of Surgical Oncology</i> , 1992, 50, 224-227.	1.7	18